Expansion of range of joint motion following treatment of systemic sclerosis with tocilizumab

Mod Rheumatol. 2015 Jan;25(1):134-7. doi: 10.3109/14397595.2013.874749. Epub 2014 Feb 18.

Abstract

Systemic sclerosis (SSc) presents stiffness of extremities due to sclerosis of the tissue especially at fingers, hands, and forearms. Here we report the case of a patient with diffuse cutaneous SSc who was administered anti-interleukin-6 receptor antibody tocilizumab (TCZ). Skin condition of SSc is evaluated by pinching the skin according to the Rodnan skin score, but sometimes tissue atrophy results in overestimation of the condition. To understand how the extremities softened after initiation of TCZ, we observed mobility of extremities. Range of motion (ROM) of joints was measured every four months after initiation of TCZ. The patient presented not only reduction of Rodnan score but also amelioration of mobility of extremities. The Rodnan skin score reduced from 35 to 7 within sixteen months, and ROM of most joints except ankle was expanded.

Keywords: Range of joint motion; Systemic sclerosis; Tocilizumab.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibodies, Monoclonal, Humanized / pharmacology*
  • Antibodies, Monoclonal, Humanized / therapeutic use
  • Female
  • Humans
  • Joints / drug effects*
  • Joints / physiopathology
  • Middle Aged
  • Range of Motion, Articular / drug effects*
  • Range of Motion, Articular / physiology
  • Scleroderma, Systemic / drug therapy*
  • Scleroderma, Systemic / physiopathology
  • Treatment Outcome

Substances

  • Antibodies, Monoclonal, Humanized
  • tocilizumab